Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 429-380-1 | CAS number: 133336-92-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
An 28-day repeated dose oral toxicity study in rats performed according to OECD 407 guideline and GLP principles is available, the NOAEL was determined to be 150 mg/kg bw/day, based on met-Hb formation.
A more recent OECD 421 study is available, in which also met-Hb measurements were included. No effects on met-Hb were observed. Based on these observations, the NOAEL based on met-Hb effects only are not considered for DNEL derivation.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 07 December 1999 - 04 January 2000
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 1995
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- 1996
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:(WI) BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: Approximately 6 weeks
- Weight at study initiation: males: 176 - 202 g; females: 154 - 175 g
- Fasting period before study: No data.
- Housing: Group housing of 5 animals per sex per cage in stainless steel suspended cages with wire mesh floors. During activity monitoring, animals were individually housed overnight in Macrolon plastic cages.
- Diet: Free access to standard pelleted laboratory animal diet (from Carfil Quality BVBA, Oud-Turnhout, Belgium)
- Water: Free access to tap-water
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS (set to maintain)
- Temperature (°C): 21 ± 3
- Humidity (%): 30 - 70
- Air changes (per hr): approximately 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 07 December 1999 To: 03 January 2000 - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
Formulations (w/w) were prepared daily within 4 hours prior to dosing. Adjustment was made for specific gravity of vehicle (1.036).
DOSE VOLUME: 5 mL/kg body weight. Actual dose volumes were calculated weekly according to the latest body weight. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Formulation analysis:
Samples of week 1 formulations were analysed to check stability over 4 hours, homogeneity (highest and lowest concentration) and accuracy of preparations (all concentrations). - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once daily, 7 days/week.
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were selected on the basis of a 5-day dose range finding study. No mortality and no clinical signs were observed in the 50, 150 and 1000 mg/kg bw/day groups. Based on the results, dose levels for the main study were selected to be 50, 150 and 1000 mg/kg bw/day.
- Positive control:
- No.
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once daily. Once prior to start of treatment and on days 8, 15, 22 and 28.
BODY WEIGHT: Yes
- Time schedule for examinations: On days 1, 8, 15, 22 and 28.
FOOD CONSUMPTION
- Weekly.
WATER CONSUMPTION
- Subjective appraisal was maintained during the study, but no quantitative investigation introduced as no effect was suspected.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: immediately prior to scheduled post mortem examination, between 7.30 and 9.30 a.m.
- Animals fasted: Yes, overnight (with a maximum of 20 hours)
- How many animals: all rats/sex/group
- Parameters checked: According to test guidelines
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: immediately prior to scheduled post mortem examination, between 7.30 and 9.30 a.m.
- Animals fasted: Yes, overnight (with a maximum of 20 hours)
- How many animals: all rats/sex/group
- Parameters checked: According to test guidelines
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes, functional observations:
During week 4 of treatment, the following tests were performed on all animals:
- hearing ability, pupillary reflex, static righting reflex and grip strength
- motor activity test (recording period: 12 hours during overnight for individual animals)
IMMUNOLOGY: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
NECROPSY:
All animals surviving to the end of the observation period (day 29) were deeply anaesthetised using ether vapour and subsequently exsanguinated. All animals assigned to the study were necropsied and descriptions of all macroscopic abnormalities recorded.
ORGAN WEIGHTS
The following organ weights (and terminal body weight) were recorded from the surviving animals on the scheduled day of necropsy: Adrenal glands, Brain, Epididymides, Heart, Kidneys, Liver, Spleen, Testes and Thymus.
HISTOPATHOLOGY: Yes
HISTOTECHNOLOGY
All organ and tissue samples (according to the guidelines), as defined under Histopathology (following), were processed, embed ded and cut at a thickness of 2-4 micrometers and stained with haematoxylin and eosin.
HISTOPATHOLOGY
Slides of all organs and tissues collected at the scheduled sacrifice from all animals of the control and the highest dose group, and all gross lesions of all animals were examined by a pathologist.
Based on the treatment related morphologic changes, the stomach was also examined from all rats of the intermediate dose groups. All abnormalities were described and included in the report. - Other examinations:
- HAEMATOLOGY: Met-haemoglobin
- Time schedule for collection of blood: immediately prior to scheduled post mortem examination, between 7.30 and 9.30 a.m.
- Animals fasted: Yes, overnight (with a maximum of 20 hours)
- How many animals: all rats/sex/group - Statistics:
- The following statistical methods were used to analyse the data:
- If the variables could be assumed to follow a normal distribution, the Dunnett-test (many to one t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.
- The Steel-test (many-one rank test) was applied when the data could not be assumed to follow a normal distribution.
- The exact Fisher-test will be applied to frequency data.
All tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance. Group means were calculated for continuous data and medians were calculated for discrete data (scores). Test statistics were calculated on the basis of exact values for means and pooled variances. - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The levels of met-haemoglobin showed an dose related increase and achieved levels of statistical significance (p<0.01) in both high dose males and females, when compared with controls. The group-mean values of met-haemoglobin for the animals of the mid dose groups did not achieve levels of statistical significance. As these values were within the range of control values, the slight increase in the mid dose groups was considered of no toxicological significance.
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not examined
- Details on results:
- Clinicals signs:
Incidental findings that were noted among treated and control animals included a wound (neck), scabs (neck), alopecia (neck, back and flanks) and salivation. These findings are commonly noted in rats of this age and strain and housed and treated under the conditions in this study and considered of no toxicological significance.
Food consumption:
The food consumption of the substance treated females showed a slight decrease at higher dose levels. In the absence of clear signs of toxicity in the females, no toxicological significance was attached to this effect. The food consumption of test substance treated males was considered to be similar to that of controls.
Haematology:
A few other haematological parameters achieved levels of statistical significance in high dose females only, comprising the erythrocyte indices, mean corpuscular volume and mean corpuscular haemoglobin, platelets and relative number of monocytes.
Based on the absence of changes in the number of erythrocytes and haemoglobin in these animals to support the changes in the erythrocyte indices and the fact that the statistical significance was only minor (p<0.05), no toxicological significance was attached to these findings.
In the absence of a clear dose response relationship and since all values are within the range of historical background data, the toxicological significance of the increased number of platelets and monocytes was doubted.
The minor statistically significant differences for white blood cells (low dose males) and platelets (low dose females) were considered to have arisen by chance. In the absence of a dose-response realtionship, no toxicological significance was attached to these findings.
Clinical Biochemistry:
In high dose males, increased levels of alanine-and aspartate-aminotransferase were found, achieving levels of statistical significance when compared to controls. Since the increases were relatively minor and were not supported by changes in liver weight and after microscopic examination of the liver, no toxicological significance was attached to these findings.
The statistical significance for the levels of urea (high dose males, p<0.05), alkaline phosphatase (low dose males, p<0.05) and inorganic phosphate (mid dose females, p<0.05) were considered to have arisen by chance, and of no toxicological significance.
Macroscopic examination:
The scab-formation seen in the neck of a high dose male confirmed the clinical signs in this animals seen during the in-life phase, and was considered a change of no toxicological significance.
Organ weights:
The statistical significance arising for the absolute and relative heart weights of high dose females was the result of a sligtly low heart weight in controls and considered to have arisen by change.
Organ weights and organ: body weight ratios of treated males were considered to be similar to those of controls.
In the absence of a dose response relationship, no toxicological significance was atatched to the minor statistically significant changes between absolute and relative thymus weights and of absolute adrenal weights in low dose females.
Functional observations:
No changes were observed in hearing ability, pupillary reflex, static righting reflex and grip strength in the animals treated with the substance, when compared to control animals. The variation in motor activity did not indicate a relation with treatment.
Analysis of dose preparations:
Analysis of the accuracy of dose preparations revealed values of approximately 90% for the high and mid dose formulations and of approximately 100% for the low dose formulation.
It should be noted that the analysed concentrations of the mid and high dose were at the border of the range of acceptability for this type of preparations (NOTOX criteria: maximum deviation s10% from prepared). The relatively low recovery in the mid and high dose preparations may be attributed to the poor solubility of the test substance in the (analytical) solvents used. Since an acceptable recovery was seen in the low dose preparation and the raw data for all dose preparations showed that the correct amounts of test substance were weighed, all dose preparations were accepted for use in this study.
The test substance preparations in propylene glycol at the concentrations tested, were considered to be homogeneous and sufficiently stable (over 4 hours) to be used in these types of studies. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 150 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- haematology
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- System:
- haematopoietic
- Organ:
- blood
- other: Formation of Met-Hb
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
- Conclusions:
- In an 28-day repeated dose oral toxicity study in rats performed according to OECD 407 guideline and GLP principles, the NOAEL was determined to be 150 mg/kg bw/day.
- Executive summary:
An 28-day repeated dose oral toxicity study in rats was performed with KY-AF according to OECD407 guideline and GLP principles. Based on the results of a 5-day dose range finding study, dose levels
for the main study were selected to be 50, 150 and 1000 mg/kg bw/day. No mortality occurred during thestudy period. There were no changes in clinical appearance, functional observations, body weights, food consumption, clinical laboratory investigations, macroscopic examination, organ weights and microscopic examination that were considered to be an effect of treatment.
The levels of met-haemoglobin showed an dose related increase and achieved levels of statistical significance (p<0.01) in both high dose (1000 mg/kg bw/day) males and females, when compared with controls. The group-mean values of met-haemoglobin for the animals of the mid dose groups did not achieve levels of statistical significance. As these values were within the range of control values, the slight increase in the mid dose groups was considered of no toxicological significance.
Based on the results of the study, the NOAEL was determined to be 150 mg/kg bw/day.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- An OECD 407 study is the required study for Annex VIII for the endpoint repeated dose toxicity.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
An 28-day repeated dose oral toxicity study in rats was performed with KY-AF according to OECD407 guideline and GLP principles. Based on the results of a 5-day dose range finding study, dose levels for the main study were selected to be 50, 150 and 1000 mg/kg bw/day. No mortality occurred during the study period. There were no changes in clinical appearance, functional observations, body weights, food consumption, clinical laboratory investigations, macroscopic examination, organ weights and microscopic examination that were considered to be an effect of treatment.
The levels of met-haemoglobin showed an dose related increase and achieved levels of statistical significance (p<0.01) in both high dose (1000 mg/kg bw/day) males and females, when compared with controls. The group-mean values of met-haemoglobin for the animals of the mid dose groups did not achieve levels of statistical significance. As these values were within the range of control values, the slight increase in the mid dose groups was considered of no toxicological significance.
Based on the results of the study, the NOAEL was determined to be 150 mg/kg bw/day.
A more recent OECD 421 study is available, in which also met-Hb measurements were included. No effects on met-Hb were observed. Based on these observations, the NOAEL based on met-Hb effects only are not considered for DNEL derivation.
Justification for classification or non-classification
Based on the available information on the substance KY-AF, the substance does not have to be classified for oral repeated dose toxicity according to Regulation (EC) no. 1272/2008 and its amendments.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.